Clinical trial NCT04301440: THE PHYSIOLOGICAL EFFECTS OF ELECTROMAGNETIC EMISSIONS ON THE GENERAL CONDITION OF THE PATIENT
Official title: THE PHYSIOLOGICAL EFFECTS OF ELECTROMAGNETIC EMISSIONS ON THE GENERAL CONDITION OF THE PATIENT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Electromagnetic Emissions and Emotional Disorder
Electromagnetic Emissions and Medication Savings
Keywords: Anxiety
Depression
Quality of life
Medication savings
Electromagnetic emissions
Lead sponsor: Clinique Bizet
Sponsor class: OTHER
First posted: 2020-03-10
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study concerns adult patients hospitalized for the management of a chronic pathology and / or its complications
Primary purpose: OTHER

Brief summary: Hospital patients usually experience anxiety caused by physiological, psychological and environmental stimuli. This emotional state corresponds to the psychophysiological response to a perceived threat.

The investigator's goal is to use a non-drug approach to these problems which would help improve the quality of life of patients, prevent the consumption of anti-anxiety drugs / antidepressants; and thus to reduce the direct cost in terms of treatment, but also to reduce the indirect costs linked to work stoppages and the consumption of the care offer.

Working hypothesis: Local magnetic muscle stimulation improves people's well-being and relaxation

Detailed description: Primary objective :

Describe the effect of the intervention on the level of anxiety / depression in patients with anxious and / or depressive characteristics

Secondary objectives:

* Describe the variation in the quality of life of patients before and after the intervention
* Describe the variation in drug consumption
* Describe the use of post intervention hospitalization
* Describe the variation in the quality of sleep before and after the intervention
* Describe the timeframe for returning patients to professional activity

Eligibility criteria: Inclusion Criteria:

* Major patient hospitalized for the management of a chronic pathology and / or its complications;
* Patient with a Hospital Anxiety and Depression scale score (HAD) ≥ 8 for items assessing anxiety disorders; AND a HAD score ≥ 8 for the items assessing depressive disorders.
* Subject affiliated to a social security scheme or beneficiary of such a scheme
* No participation in another clinical study

Exclusion Criteria:

* Minor patient
* Pregnant and breastfeeding women
* HAD score \<8 for items evaluating anxiety disorders OR a HAD score \<8 for items evaluating depressive disorders
* Major subject protected by law, under curatorship or tutorship

Primary outcomes:
measure: Improved quality of life in depressed and anxiety patients: Hospital Anxiety and Depression scale
timeFrame: Ten days
measure: Decreased consumption of anti-anxiety and anti-depressant drugs
timeFrame: Ten days
measure: Improved quality of sleep: Epworth scale
timeFrame: Ten days
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Benkessou
Study officials:
References: